Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

Now Viewing

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

1. Dr Ajai Chari to Dr Callander: What factors (disease or patient) do you consider when deciding between a triplet vs quadruplet induction regimen for those who are transplant ineligible?
2. Dr Ajai Chari to Dr Raje: What unmet needs still exist in the treatment paradigm of newly diagnosed multiple myeloma, both transplant eligible and ineligible?

Related Videos